Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome

Interleukin-1 (IL-1)-blocking therapies are effective in reducing disease severity and inflammation in Schnitzler syndrome. Here, we present a patient with Schnitzler syndrome treated successfully using canakinumab for over 10 years. Complete clinical response was associated with a decrease in derma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bossart, Simon, Seyed Jafari, S. Morteza, Heidemeyer, Kristine, Yan, Kexiang, Feldmeyer, Laurence, Borradori, Luca, Yawalkar, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050468/
https://www.ncbi.nlm.nih.gov/pubmed/37007766
http://dx.doi.org/10.3389/fmed.2023.1050230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050468/
https://www.ncbi.nlm.nih.gov/pubmed/37007766
http://dx.doi.org/10.3389/fmed.2023.1050230

Ejemplares similares